{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"data_sharing_plan":["IPD Sharing (as of January 2020): No"],"condition":["Apatinib","Outcome, Fatal","Colorectal Cancer","Colorectal Neoplasms","Adjuvant Chemotherapy"],"disease":["Apatinib","Outcome, Fatal","Colorectal Cancer","Colorectal Neoplasms","Adjuvant Chemotherapy"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2250127"],"location":["China"],"study_start_month":["3"],"keyword":["Apatinib"],"repository":["ECRIN MDR"],"study_status":["Withdrawn"],"additional_accession":[]},"is_claimable":false,"name":"Apatinib for Resectable Colorectal Cancer","description":"Objective: To compare the outcome of patients with colorectal cancer who treated with adjuvant therapy or Apatinib with adjuvant therapy postoperatively.\nLanguage: English.","dates":{"creation":"2020-03-15"},"accession":"2250127","cross_references":{"ClinicalTrials___gov":["NCT03228043"]}}